There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
RRx-001 is a pleiotropic anticancer agent in phase III clinical trials, which polarizes tumor-associated macrophages from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype. In vitro, RRx-001 was found to decrease the expression levels of CD47 and SIRPα on tumor cells and monocytes/macrophages, respectively, reducing the phagocytosis inhibitory function of the CD47/SIRPα interaction[1]. RRx-001 has nephro-, geno- and myeloprotective effects in vivo. Importantly, RRx-001 did not protect sarcoma-180 solid tumor xenografts against cisplatin-induced cytotoxicity[2]. RRx-001 is demonstrated to induce Nrf2 in normal tissues, mediating protection, and to downregulate the Nrf2-controlled antiapoptotic target gene, B-cell lymphoma 2 (Bcl-2) in tumors, mediating cytotoxicity[3]. Higher doses of RRx-001 (100, 1000 micro molar) significantly decreased erythrocyte deformability under hypoxia. Co-administration of RRx-001 and nitrite under hypoxic conditions results in a significant increase in erythrocyte deformability that is related to increased NO production[4].
RRx-001 细胞实验
Cell Line
Concentration
Treated Time
Description
References
LLC cells
100 µg/mL
12 hours
To evaluate the inhibitory effect of LRT nanomedicine on calcium influx in LLC cells, results showed that LRT significantly inhibited calcium ion uptake.
Nat Commun. 2023 Nov 11;14(1):7306.
LLC cells
100 µg/mL
24 hours
To observe the intracellular calcium levels in LLC cells treated with LRT by CLSM, results showed a significant reduction in intracellular calcium levels.
Nat Commun. 2023 Nov 11;14(1):7306.
HCT 116 colon cancer cells
0.5 µM
24 hours
Induced transcription of interferon-responsive genes, sustained for up to 4 weeks post-exposure
Clin Epigenetics. 2017 Jan 19;9:4.
A549 cells
2 µM
24 hours
RRx-001 decreased the protein levels of CD47 and SIRPα, indicating that it disrupted the CD47-SIRPα interaction and promoted phagocytosis.
Transl Oncol. 2019 Apr;12(4):626-632.
M2 polarized bone marrow-derived macrophages (BMDM)
2 µM
24 hours
RRx-001 significantly increased the mRNA expression levels of M1 markers CD80 and CD86, indicating that it polarized macrophages from the M2 phenotype to the M1 phenotype.
Transl Oncol. 2019 Apr;12(4):626-632.
Bone marrow-derived macrophages (BMDMs)
100-300 nM
30 minutes
RRx-001 dose-dependently inhibited IL-1β secretion, caspase-1 cleavage, and cell death, indicating its inhibitory effect on NLRP3 inflammasome activation.
Cell Mol Immunol. 2021 Jun;18(6):1425-1436.
HUVEC
5 µM
30 minutes
To assess the adhesion of RBCs to endothelial cells after RRx-001 treatment, results showed that RRx-001 significantly increased RBC adhesion under TNFα-induced inflammation and hypoxia
Int J Mol Sci. 2021 Apr 29;22(9):4713.
J82 cells
0.5-5 µM
48 hours
To evaluate the cytotoxic effect of RRx-001 on bladder cancer cells, results showed that RRx-001 exhibited cytotoxic effects at 48 hours.
J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.
T24 cells
0.5-5 µM
48 hours
To evaluate the cytotoxic effect of RRx-001 on bladder cancer cells, results showed that RRx-001 exhibited cytotoxic effects at 48 hours.
J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.
5637 cells
0.5-5 µM
48 hours
To evaluate the cytotoxic effect of RRx-001 on bladder cancer cells, results showed that RRx-001 exhibited cytotoxic effects at 48 hours.
J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.
KU-19-19 cells
0.5-5 µM
48 hours
To evaluate the cytotoxic effect of RRx-001 on bladder cancer cells, results showed that RRx-001 exhibited cytotoxic effects at 48 hours.
J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.
AU-565, MCF-7, and MDA-MB-231 breast cancer cells
2 µM
8 hours
RRx-001 significantly increased the phagocytosis of breast cancer cells.
Transl Oncol. 2019 Apr;12(4):626-632.
RRx-001 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c Nude mice
A549 xenograft model
Intraperitoneal injection
10 mg/kg
Twice a week, continuous treatment
RRx-001 significantly inhibited tumor growth, but its antitumor activity was attenuated when macrophages were depleted by clodronate.
Transl Oncol. 2019 Apr;12(4):626-632.
Mice
HDM-induced allergic asthma model
Intraperitoneal injection
10 mg/kg
Injected on days 7, 9, and 11, continued until day 14
RRx-001 significantly inhibited HDM-induced airway inflammation and mucus secretion, reduced the infiltration of eosinophils, neutrophils, and lymphocytes, and decreased the levels of total IgE and HDM-specific IgE in serum.
Front Immunol. 2021 Aug 3;12:718779
Mice
Heterotopic GCT model
Intraperitoneal injection
10 mg/kg
Every other day, for three weeks
RRX-001 treatment significantly inhibited the in vivo growth of GCT cells, with both tumor size and weight significantly reduced
Once daily for 10 days (DSS-induced colitis); every 2 days for 22 days (EAE)
RRx-001 significantly alleviated the symptoms of LPS-induced systemic inflammation, DSS-induced colitis, and EAE, demonstrating its therapeutic potential in NLRP3-driven disease models.
Cell Mol Immunol. 2021 Jun;18(6):1425-1436.
Mice
SCCVII and U87 tumor models
Intravenous injection
15 mg/kg
Single dose
To examine the microregional effects of RRx-001 on tumor blood flow and oxygenation, results showed that RRx-001 caused a loss of perfusion in large regions of the tumor, but perfusion recovered after 12 hours.
Clin Epigenetics. 2016 May 11;8:53
C57BL/6J mice
Orthotopic lung cancer model
Intravenous injection
40 mg/kg
Every other day, for a total of three injections
To evaluate the therapeutic efficacy of LRT nanomedicine in the orthotopic lung cancer model, results showed that LRT significantly inhibited tumor growth and prolonged the survival of mice.
Nat Commun. 2023 Nov 11;14(1):7306.
Mice
Nu/nu mice
Intravenous injection
5 mg/kg and 10 mg/kg
Every 72 hours for 2 weeks
To assess the localization and tumor viability of RRx-001 treated RBCs, results showed that RRx-001 treated RBCs preferentially localized to tumors and significantly reduced tumor volume
Int J Mol Sci. 2021 Apr 29;22(9):4713.
CB-17 SCID mice
MM.1S xenograft model
Intravenous injection
5 mg/kg or 10 mg/kg
Three times weekly for 24 days
RRx-001 significantly inhibited tumor growth and enhanced survival
搜索
HazMat Fee +
